Publication | Closed Access

Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer

UrologyMedicinePharmacologyPharmacotherapyCastration-resistant Prostate CancerAnti-cancer AgentCancer TreatmentProstatic DiseaseOncologyAndrogen Receptor ConfersEndocrine-related CancerDrug Discovery